换一批A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
第一作者：
Annette S,Little
第一单位：
Laboratory of Molecular Signalling, Babraham Institute, Cambridge, UK. annette.little@bbsrc.ac.uk
作者：
医学主题词
苯咪唑类(Benzimidazoles);细胞周期(Cell Cycle);细胞死亡(Cell Death);细胞系, 肿瘤(Cell Line, Tumor);结直肠肿瘤(Colorectal Neoplasms);抗药性, 肿瘤(Drug Resistance, Neoplasm);基因扩增(Gene Amplification);基因, ras(Genes, ras);人类(Humans);MAP激酶信号系统(MAP Kinase Signaling System);丝裂原激活蛋白激酶激酶类(Mitogen-Activated Protein Kinase Kinases);原癌基因蛋白质类(Proto-Oncogene Proteins);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);原癌基因蛋白质类p21(ras)(Proto-Oncogene Proteins p21(ras));增量调节(Up-Regulation);ras蛋白质类(ras Proteins)
DOI
10.1126/scisignal.4170er2
PMID
21674991
发布时间
2019-12-10
- 浏览13
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
